Miplyffa Alternatives Compared
Miplyffa (arimoclomol) | Miglustat | Aqneursa (levacetylleucine) |
|
---|
Miplyffa (arimoclomol) | Miglustat | Aqneursa (levacetylleucine) |
|
|||||||||||||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Prescription only
Prescribed for Niemann-Pick Disease. Miplyffa may also be used for purposes not listed in this medication guide. |
Prescription only
Prescribed for Gaucher Disease, Niemann-Pick Disease, Pompe Disease. Miglustat may also be used for purposes not listed in this medication guide. |
Prescription only
Prescribed for Niemann-Pick Disease. Aqneursa may also be used for purposes not listed in this medication guide. |
Related suggestions Niemann-Pick Disease
|
|||||||||||||||||||||||
More about Miplyffa (arimoclomol) | More about Miglustat | More about Aqneursa (levacetylleucine) | ||||||||||||||||||||||||
Ratings & Reviews | ||||||||||||||||||||||||||
Be the first to share your experience with this drug. |
Miglustat has an average rating of 8.0 out of 10 from a total of 1 ratings on Drugs.com. 100% of reviewers reported a positive effect, while 0% reported a negative effect. |
Be the first to share your experience with this drug. |
||||||||||||||||||||||||
Side Effects Experienced by Users Side effects are reported in Drugs.com user reviews and not clinically verified. | ||||||||||||||||||||||||||
View all Miplyffa side effects |
View all Miglustat side effects |
View all Aqneursa side effects |
||||||||||||||||||||||||
Drug Class | ||||||||||||||||||||||||||
Generic Availability | ||||||||||||||||||||||||||
Lower cost generic |
||||||||||||||||||||||||||
Pricing and Coupons * Prices are without insurance | ||||||||||||||||||||||||||
View all Miplyffa prices |
View all Miglustat prices |
View all Aqneursa prices |
||||||||||||||||||||||||
Dosage Forms | ||||||||||||||||||||||||||
|
|
|
||||||||||||||||||||||||
Brand Names | ||||||||||||||||||||||||||
N/A |
Opfolda, Yargesa, Zavesca |
N/A |
||||||||||||||||||||||||
Half Life Drug half-life is the time required for plasma concentration to reduce to half its original value. | ||||||||||||||||||||||||||
4 hours |
7 hours |
1 hour |
||||||||||||||||||||||||
CSA Schedule 1 View glossary of CSA terms | ||||||||||||||||||||||||||
Not a controlled drug
Is not subject to the Controlled Substances Act. |
Not a controlled drug
Is not subject to the Controlled Substances Act. |
Not a controlled drug
Is not subject to the Controlled Substances Act. |
||||||||||||||||||||||||
Pregnancy Category | ||||||||||||||||||||||||||
Summary unavailable. See the full pregnancy warnings document. |
Category C
Risk cannot be ruled out
See the full pregnancy warnings document. |
Summary unavailable. See the full pregnancy warnings document. |
||||||||||||||||||||||||
Drug Interactions | ||||||||||||||||||||||||||
A total of 8 drugs are known to interact with Miplyffa:
|
A total of 1 drugs are known to interact with Miglustat:
|
A total of 86 drugs are known to interact with Aqneursa:
|
||||||||||||||||||||||||
Alcohol/Food/Lifestyle Interactions | ||||||||||||||||||||||||||
No known alcohol/food interactions. This does not necessarily mean no interactions exist. Always consult your healthcare provider. |
|
No known alcohol/food interactions. This does not necessarily mean no interactions exist. Always consult your healthcare provider. |
||||||||||||||||||||||||
Disease Interactions | ||||||||||||||||||||||||||
First Approval Date | ||||||||||||||||||||||||||
September 20, 2024 |
July 31, 2003 |
N/A |
||||||||||||||||||||||||
WADA Class View classifications | ||||||||||||||||||||||||||
N/A |
N/A |
N/A |
||||||||||||||||||||||||
More Information | ||||||||||||||||||||||||||
Patient Resources | ||||||||||||||||||||||||||
Professional Resources | ||||||||||||||||||||||||||
Related Treatment Guide | ||||||||||||||||||||||||||
1 The Controlled Substances Act (CSA) schedule information displayed applies to substances regulated under federal law. There may be variations in CSA schedules between individual states.
See also:
Further information
Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.